Abbisko Cayman (HKSE:02256) Net Cash per Share : HK$3.10 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Abbisko Cayman's Net Cash per Share for the quarter that ended in Dec. 2023 was HK$3.10.

The historical rank and industry rank for Abbisko Cayman's Net Cash per Share or its related term are showing as below:

HKSE:02256' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.84 Med: 1.18 Max: 1.92
Current: 1.02

During the past 5 years, the highest Price-to-Net-Cash Ratio of Abbisko Cayman was 1.92. The lowest was 0.84. And the median was 1.18.

HKSE:02256's Price-to-Net-Cash is ranked better than
87.37% of 863 companies
in the Biotechnology industry
Industry Median: 4.11 vs HKSE:02256: 1.02

Abbisko Cayman Net Cash per Share Historical Data

The historical data trend for Abbisko Cayman's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Net Cash per Share Chart

Abbisko Cayman Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

-0.78

-1.95

4.73

3.81

3.10

Abbisko Cayman Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Cash per Share	Get a 7-Day Free Trial			4.73	4.44	3.81	3.52	3.10

Competitive Comparison of Abbisko Cayman's Net Cash per Share

For the Biotechnology subindustry, Abbisko Cayman's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abbisko Cayman's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's Price-to-Net-Cash falls into.

Abbisko Cayman Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Abbisko Cayman's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2157.379	-	146.873	-	0)	/	647.858
=	3.10

Abbisko Cayman's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

	Net Cash per Share (Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2157.379	-	146.873	-	0)	/	647.858
=	3.10

Abbisko Cayman (HKSE:02256) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Abbisko Cayman Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbisko Cayman (HKSE:02256) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

8ZD:Germany

Address

Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

https://www.abbisko.com

Abbisko Cayman Ltd is a investment holding company it operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.

Executives

Lav Asset Management (hong Kong) Limited	2102 Investment manager
Shi Yi	2201 Interest of corporation controlled by you
Xu Yao-chang	2101 Beneficial owner
Yu Hongping	2501 Other
Chen Zhui	2501 Other
Futu Trustee Limited	2301 Trustee
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Yu Hongping	2501 Other
Morgan Stanley	2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited
Trident Trust Company (hk) Limited	2301 Trustee
Computershare Hong Kong Trustees Limited	2301 Trustee
Morgan Stanley Investments (uk)	2201 Interest of corporation controlled by you
Morgan Stanley International Limited	2201 Interest of corporation controlled by you
Morgan Stanley International Holdings Inc.	2201 Interest of corporation controlled by you

Abbisko Cayman (HKSE:02256) Headlines

No Headlines